ACRS Stock Price, Aclaris Therapeutics Inc Quote, Chart

Market Summary

USD1.21-0.01

Market Closed

-0.82%

ACRS Stock Price

View Fullscreen

ACRS RSI Chart

ACRS Valuation

Market Cap

85.8M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

2.75

EV/EBITDA

-0.52

Price/Free Cashflow

-1.08

ACRS Price/Sales (Trailing)

ACRS Profitability

Operating Margin

89.05%

EBT Margin

-284.32%

Return on Equity

-56.29%

Return on Assets

-44.82%

Free Cashflow Yield

-92.79%

ACRS Fundamentals

ACRS Revenue

Revenue (TTM)

31.2M

Rev. Growth (Yr)

126.62%

Rev. Growth (Qtr)

89.29%

ACRS Earnings

Earnings (TTM)

-88.5M

Earnings Growth (Yr)

94.6%

Earnings Growth (Qtr)

94.9%

Breaking Down ACRS Revenue

Last 7 days

-0.8%

Last 30 days

-2.4%

Last 90 days

4.3%

Trailing 12 Months

-86.9%

How does ACRS drawdown profile look like?

ACRS Financial Health

Current Ratio

4.16

Debt/Equity

0.07

Debt/Cashflow

-7.3

ACRS Investor Care

Shares Dilution (1Y)

6.35%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	30.8M	31.2M	21.4M	31.2M
2022	6.4M	6.1M	23.5M	29.8M
2021	6.9M	6.6M	6.8M	6.8M
2020	4.4M	5.5M	6.0M	6.5M
2019	9.7M	6.9M	6.8M	4.2M
2018	2.9M	6.5M	6.9M	9.6M
2017	0	0	941.5K	1.8M
2015	25.0K	51.3K	77.7K	104.0K
2014	19.3K	0	17.7K	16.0K
2013	0	0	0	21.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aclaris Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	walker neal	sold (taxes)	-4,062	1.26	-3,224	interim president and ceo
Apr 01, 2024	walker neal	acquired	-	-	9,467	interim president and ceo
Mar 04, 2024	powell andrew kenneth william	bought	7,500	1.25	6,000	-
Mar 02, 2024	balthaser kevin	sold (taxes)	-529	1.24	-427	chief financial officer
Mar 02, 2024	balthaser kevin	acquired	-	-	1,500	chief financial officer
Mar 02, 2024	monahan joseph	acquired	-	-	12,500	chief scientific officer
Mar 02, 2024	monahan joseph	sold (taxes)	-4,378	1.24	-3,531	chief scientific officer
Mar 01, 2024	powell andrew kenneth william	bought	10,455	1.23	8,500	-
Mar 01, 2024	walker neal	sold (taxes)	-3,996	1.24	-3,223	interim president and ceo
Mar 01, 2024	monahan joseph	acquired	-	-	60,925	chief scientific officer

Which funds bought or sold ACRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 29, 2024	China Universal Asset Management Co., Ltd.	added	66.26	8,000	17,000	-%
Apr 29, 2024	PRINCIPAL FINANCIAL GROUP INC	reduced	-9.09	1,501	21,891	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	34,000	34,000	-%
Apr 25, 2024	Lindbrook Capital, LLC	sold off	-100	-402	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-17.57	-7,853	288,636	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	sold off	-100	-45,973	-	-%
Apr 25, 2024	Chicago Partners Investment Group LLC	sold off	-100	-26,445	-	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	unchanged	-	8,000	52,000	-%
Apr 24, 2024	BML Capital Management, LLC	added	1,338	10,965,200	11,651,000	7.68%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.45	-7,000	3,000	-%

Are Funds Buying or Selling ACRS?

Are funds buying ACRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACRS

No. of Funds

Unveiling Aclaris Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rock springs capital management lp	4.23%	2,998,495	SC 13G/A
Feb 14, 2024	venrock healthcare capital partners ii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	-	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	6.1%	6	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	0%	0	SC 13G/A
Feb 14, 2024	millennium management llc	5.3%	3,769,926	SC 13G
Feb 14, 2024	tang capital partners lp	2.5%	1,753,335	SC 13G/A
Feb 13, 2024	foresite capital fund iv, l.p.	0.0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	6.67%	4,721,887	SC 13G
Feb 08, 2024	bml investment partners, l.p.	13.3%	9,395,934	SC 13G/A

Recent SEC filings of Aclaris Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Mar 19, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Feb 27, 2024	10-K	Annual Report

Peers (Alternatives to Aclaris Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.7B	23.7B	-1.24%	2.02%	41.5	7.7	-8.94%	-35.72%
IDXX	40.9B	3.7B	-8.74%	0.65%	48.45	11.18	8.72%	24.44%
A	40.2B	6.7B	-5.82%	0.71%	32.49	5.96	-2.81%	-6.58%
DGX	15.4B	9.3B	3.81%	-0.93%	18.14	1.65	-3.29%	6.68%
MEDP	12.0B	2.0B	-3.91%	88.07%	38.5	6.13	25.57%	21.62%
CRL	11.8B	4.1B	-15.48%	20.46%	24.78	2.85	3.86%	-2.39%
NTRA	11.2B	1.1B	1.55%	76.98%	-25.8	10.36	31.99%	20.63%
EXAS	10.8B	2.5B	-14.06%	-6.40%	-52.77	4.31	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-21.86%	-28.69%	1.7K	2.87	28.93%	111.61%
GH	2.2B	563.9M	-12.75%	-20.04%	-4.57	3.88	25.45%	26.76%
SMALL-CAP
CDNA	401.8M	280.3M	-26.72%	-6.51%	-2.11	1.43	-12.89%	-148.37%
ACRS	85.8M	31.2M	-2.42%	-86.92%	-0.97	2.75	5.03%	-1.81%
APDN	67.9M	9.0M	875.61%	304.04%	-9.4	7.55	-53.31%	2.21%
AWH	39.7M	9.2M	3.87%	-30.75%	-2.38	4.34	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Aclaris Therapeutics Inc News

Latest updates

Aclaris Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	89.3%	17,570,000	9,282,000	1,869,000	2,528,000	7,753,000	19,018,000	1,528,000	1,453,000	1,501,000	1,659,000	1,824,000	1,777,000	1,580,000	1,449,000	2,046,000	1,407,000	1,095,000	983,000	886,000	1,263,000	3,669,000
Cost Of Revenue	-14.5%	725,000	848,000	1,042,000	808,000	877,000	923,000	1,068,000	1,155,000	1,149,000	1,099,000	1,263,000	1,202,000	1,286,000	1,189,000	1,389,000	1,269,000	1,027,500	826,000	994,000	1,207,000	1,190,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	160,000
Costs and Expenses	-47.1%	21,617,000	40,859,000	33,684,000	32,446,000	36,832,000	39,892,000	22,522,000	20,360,000	24,394,000	21,954,000	19,830,000	30,306,000	15,140,000	11,914,000	13,427,000	16,913,000	13,058,000	23,847,000	55,656,000	28,314,000	13,283,500
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39,198,000
S&GA Expenses	15.8%	8,214,000	7,091,000	8,317,000	8,790,000	7,146,000	5,813,000	6,075,000	6,099,000	6,943,000	5,979,000	5,870,000	4,827,000	4,898,500	3,859,000	5,572,000	6,200,000	6,056,000	6,838,000	7,469,000	7,464,000	13,884,500
R&D Expenses	11.6%	26,646,000	23,876,000	25,275,000	22,587,000	21,072,000	23,656,000	18,779,000	14,306,000	14,102,000	13,976,000	7,897,000	7,838,000	8,955,500	6,240,000	6,466,000	7,677,000	10,825,500	16,183,000	17,519,000	19,643,000	18,710,500
EBITDA Margin	-Infinity%	-2.82	-	-2.76	-2.79	-2.89	-3.83	-14.67	-13.99	-13.30	-7.46	-7.64	-7.34	-7.72	-	-	-	-	-	-	-	-
EBT Margin	-Infinity%	-2.84	-	-2.79	-2.82	-2.92	-3.87	-14.80	-14.12	-13.44	-7.51	-7.74	-7.49	-7.92	-	-	-	-	-	-	-	-
Net Income	94.9%	-1,491,000	-29,261,000	-29,569,000	-28,160,000	-27,635,000	-19,952,000	-20,532,000	-18,789,000	-22,804,000	-21,146,000	-18,161,000	-28,754,000	-13,173,000	-10,659,000	-11,597,000	-15,586,000	-18,594,000	-55,319,000	-49,876,000	-37,565,000	-38,551,000
Net Income Margin	47.1%	-2.83	-5.35	-3.38	-3.12	-2.92	-3.49	-13.56	-12.57	-13.44	-11.88	-10.67	-9.37	-	-	-	-	-	-	-	-	-
Free Cashflow	70.8%	-7,202,000	-24,641,000	-20,885,000	-26,906,000	-19,220,000	-7,967,000	-19,852,000	-21,133,000	-17,275,000	-10,662,000	-12,229,000	-12,240,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-9.6%	197	218	236	230	255	268	278	227	251	263	288	161	71.00	72.00	85.00	97.00	98.00	160	217	253	276
Current Assets	4.7%	129	123	133	184	232	257	259	191	205	206	241	135	57.00	58.00	71.00	83.00	84.00	145	138	157	179
Cash Equivalents	2.1%	40.00	39.00	31.00	45.00	45.00	62.00	68.00	36.00	27.00	54.00	113	35.00	22.00	25.00	33.00	54.00	36.00	30.00	32.00	34.00	57.00
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	1.00	1.00
Net PPE	-8.2%	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00	2.00
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.00	-	-	19.00	19.00
Liabilities	-35.1%	40.00	62.00	56.00	53.00	57.00	48.00	42.00	46.00	54.00	47.00	54.00	49.00	33.00	31.00	36.00	39.00	28.00	75.00	80.00	71.00	60.00
Current Liabilities	13.3%	31.00	27.00	23.00	18.00	22.00	20.00	16.00	17.00	23.00	18.00	15.00	15.00	15.00	13.00	18.00	21.00	22.00	39.00	43.00	36.00	27.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	11.00	11.00	11.00	11.00	11.00	11.00	-	30.00	30.00	30.00	30.00
Shareholder's Equity	0.5%	157	156	180	177	198	220	236	180	197	217	234	112	38.00	41.00	49.00	58.00	70.00	85.00	137	182	215
Retained Earnings	-0.2%	-770	-769	-740	-710	-682	-654	-634	-614	-595	-572	-551	-533	-504	-491	-480	-469	-453	-434	-379	-329	-292
Additional Paid-In Capital	0.1%	928	927	921	888	881	876	872	795	793	789	785	646	542	532	530	527	524	520	517	512	507
Shares Outstanding	0.1%	71.00	71.00	71.00	67.00	67.00	65.00	64.00	61.00	57.00	61.00	52.00	50.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	713	-	-	-	898	-	-	-	915	-	-	-	66.00	-	-	-	80.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	72.5%	-6,761	-24,557	-20,654	-26,353	-19,115	-7,817	-19,666	-20,969	-17,075	-10,606	-12,221	-12,232	-8,857	-12,150	-10,821	-6,805	-20,390	-23,359	-21,378	-31,318	-27,248
Share Based Compensation	-78.7%	1,266	5,948	6,522	6,806	4,813	4,188	3,692	2,346	3,851	3,702	3,832	2,675	2,504	1,941	3,309	3,453	3,181	3,320	4,814	4,862	4,956
Cashflow From Investing	-76.8%	7,550	32,534	-19,662	25,798	2,702	1,217	-21,223	29,932	-9,176	-37,672	-45,470	-75,314	-2,305	5,237	-10,487	13,942	56,438	21,673	18,952	8,616	-70,506
Cashflow From Financing	156.3%	49.00	-87.00	-	-	37.00	-11.00	72,811	30.00	-2.00	-11,567	135,871	100,750	7,829	-278	-97.00	10,918	-30,009	-70.00	-117	-120	128,183

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACRS Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenue	$ 31,249	$ 29,752	$ 6,761
Costs and expenses:
Cost of revenue	3,423	4,023	4,713
Research and development	98,384	77,813	43,813
General and administrative	32,412	25,133	23,619
Licensing	14,658	7,937
Revaluation of contingent consideration	(26,900)	4,700	24,339
Intangible asset impairment	6,629
Total costs and expenses	128,606	119,606	96,484
Loss from operations	(97,357)	(89,854)	(89,723)
Other income (expense), net	8,509	2,946	(1,142)
Loss before income taxes	(88,848)	(86,908)	(90,865)
Income tax benefit	(367)
Net loss	$ (88,481)	$ (86,908)	$ (90,865)
Net loss per share, basic	$ (1.27)	$ (1.33)	$ (1.60)
Net loss per share, diluted	$ (1.27)	$ (1.33)	$ (1.60)
Weighted average common shares outstanding, basic	69,808,855	65,213,944	56,730,583
Weighted average common shares outstanding, diluted	69,808,855	65,213,944	56,730,583
Other comprehensive loss:
Unrealized gain (loss) on marketable securities, net of tax of $0	$ 791	$ (673)	$ (229)
Foreign currency translation adjustment			99
Total other comprehensive gain (loss)	791	(673)	(130)
Comprehensive loss	(87,690)	(87,581)	(90,995)
Contract research
Revenues:
Total revenue	3,035	4,395	5,830
Licensing
Revenues:
Total revenue	$ 28,214	25,100	809
Other
Revenues:
Total revenue		$ 257	$ 122

ACRS Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 39,878	$ 45,277
Short-term marketable securities	79,228	172,294
Accounts receivable, net	298	484
Prepaid expenses and other current assets	9,452	13,495
Total current assets	128,856	231,550
Marketable securities	62,771	12,242
Property and equipment, net	1,620	1,099
Intangible assets	269	6,973
Other assets	3,889	2,732
Total assets	197,405	254,596
Current liabilities:
Accounts payable	8,878	10,351
Accrued expenses	19,446	8,701
Current portion of lease liabilities	426	684
Discontinued operations	2,202	2,202
Total current liabilities	30,952	21,938
Other liabilities	3,074	1,570
Contingent consideration	6,200	33,100
Deferred tax liability		367
Total liabilities	40,226	56,975
Commitments and contingencies (Note 17)
Stockholders' Equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued or outstanding at December 31, 2023 and December 31, 2022
Common stock, $0.00001 par value; 200,000,000 and 100,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 70,894,889 and 66,688,647 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	1	1
Additional paidin capital	928,080	880,832
Accumulated other comprehensive loss	(106)	(897)
Accumulated deficit	(770,796)	(682,315)
Total stockholders' equity	157,179	197,621
Total liabilities and stockholders' equity	$ 197,405	$ 254,596

About Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

CEO	Dr. Douglas J. Manion Frcp(C), M.D.
WEBSITE	aclaristx.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	100

Aclaris Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aclaris Therapeutics Inc? What does ACRS stand for in stocks?

ACRS is the stock ticker symbol of Aclaris Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aclaris Therapeutics Inc (ACRS)?

As of Tue Apr 30 2024, market cap of Aclaris Therapeutics Inc is 85.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers.

What is the fair value of ACRS stock?

You can check ACRS's fair value in chart for subscribers. The fair value of Aclaris Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aclaris Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aclaris Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ACRS is over valued or under valued. Whether Aclaris Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aclaris Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRS.

What is Aclaris Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, ACRS's PE ratio (Price to Earnings) is -0.97 and Price to Sales (PS) ratio is 2.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRS PE ratio will change depending on the future growth rate expectations of investors.